Vitamin E in the primary prevention of cardiovascular disease and cancer - The Women's Health Study: A randomized controlled trial

被引:818
作者
Lee, IM
Cook, NR
Gaziano, JM
Gordon, D
Ridker, PM
Manson, JE
Hennekens, CH
Buring, JE
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Prevent Med, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Cardiovasc Med, Boston, MA 02215 USA
[3] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Aging, Boston, MA 02215 USA
[4] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[5] Vet Affairs Boston Healthcare Syst, Boston, MA USA
[6] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA
[7] Univ Miami, Sch Med, Dept Med, Miami, FL USA
[8] Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL USA
[9] Florida Atlantic Univ, Ctr Excellence, Dept Biomed Sci, Boca Raton, FL 33431 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2005年 / 294卷 / 01期
关键词
D O I
10.1001/jama.294.1.56
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Basic research provides plausible mechanisms and observational studies suggest that apparently healthy persons, who self-select for high intakes of vitamin E through diet or supplements, have decreased risks of cardiovascular disease and cancer. Randomized trials do not generally support benefits of vitamin E, but there are few trials of long duration among initially healthy persons. Objective To test whether vitamin E supplementation decreases risks of cardiovascular disease and cancer among healthy women. Design, Setting, and Participants In the Women's Health Study conducted between 1992 and 2004, 39 876 apparently healthy US women aged at least 45 years were randomly assigned to receive vitamin E or placebo and aspirin or placebo, using a 2 X 2 factorial design, and were followed up for an average of 10.1 years. Intervention Administration of 600 IU of natural-source vitamin E on alternate days. Main Outcome Measures Primary outcomes were a composite end point of first major cardiovascular event (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and total invasive cancer. Results During follow-up, there were 482. major cardiovascular events in the vitamin E group and 517 in the placebo group, a nonsignificant 7% risk reduction (relative risk [RR], 0.93; 95% confidence interval [CI], 0.82-1.05; P=.26). There were no significant effects on the incidences of myocardial infarction (RR, 1.01; 95% Cl, 0.82-1.23; P=.96) or stroke (RR, 0.98; 95% Cl, 0.82-1.17; P=.82), as well as ischemic or hemorrhagic stroke. For cardiovascular death, there was a significant 24% reduction (RR, 0.76; 95% Cl, 0.59-0.98; P=.03). There was no significant effect on the incidences of total cancer (1437 cases in the vitamin E group and 1428 in the placebo group; RR, 1.01; 95% Cl, 0.94-1.08; P=.87) or breast (RR, 1.00; 95% Cl, 0.90-1.12; P=.95), lung (RR, 1.09; 95% Cl, 0.83-1.44; P=.52), or colon cancers (RR, 1.00; 95% Cl, 0.77-1.31; P=.99). Cancer deaths also did not differ significantly between groups. There was no significant effect of vitamin E on total mortality (636 in the vitamin E group and 615 in the placebo group; RR, 1.04; 95% Cl, 0.93-1.16; P=.53). Conclusions The data from this large trial indicated that 600 IU of natural-source vitamin E taken every other day provided no overall benefit for major cardiovascular events or cancer, did not affect total mortality, and decreased cardiovascular mortality in healthy women. These data do not support recommending vitamin E supplementation for cardiovascular disease or cancer prevention among healthy women.
引用
收藏
页码:56 / 65
页数:10
相关论文
共 57 条
  • [1] Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
  • [2] Interobserver agreement in the classification of stroke in the Women's Health Study
    Atiya, M
    Kurth, T
    Berger, K
    Buring, JE
    Kase, CS
    [J]. STROKE, 2003, 34 (02) : 565 - 567
  • [3] A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients
    Bairati, I
    Meyer, F
    Gélinas, M
    Fortin, A
    Nabid, A
    Brochet, F
    Mercier, JP
    Têtu, B
    Harel, F
    Mâsse, B
    Vigneault, E
    Vass, S
    del Vecchio, P
    Roy, J
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (07): : 481 - 488
  • [4] NUTRITION INTERVENTION TRIALS IN LINXIAN, CHINA - SUPPLEMENTATION WITH SPECIFIC VITAMIN MINERAL COMBINATIONS, CANCER INCIDENCE, AND DISEASE-SPECIFIC MORTALITY IN THE GENERAL-POPULATION
    BLOT, WJ
    LI, JY
    TAYLOR, PR
    GUO, WD
    DAWSEY, S
    WANG, GQ
    YANG, CS
    ZHENG, SF
    GAIL, M
    LI, GY
    YU, Y
    LIU, BQ
    TANGREA, J
    SUN, YH
    LIU, FS
    FRAUMENI, JF
    ZHANG, YH
    LI, B
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (18): : 1483 - 1492
  • [5] Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial
    Boaz, M
    Smetana, S
    Weinstein, T
    Matas, Z
    Gafter, U
    Iaina, A
    Knecht, A
    Weissgarten, Y
    Brunner, D
    Fainaru, M
    Green, MS
    [J]. LANCET, 2000, 356 (9237) : 1213 - 1218
  • [6] Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
    Brown, BG
    Zhao, XQ
    Chait, A
    Fisher, LD
    Cheung, MC
    Morse, JS
    Dowdy, AA
    Marino, EK
    Bolson, EL
    Alaupovic, P
    Frohlich, J
    Albers, JJ
    Serafini, L
    Huss-Frechette, E
    Wang, S
    DeAngelis, D
    Dodek, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (22) : 1583 - 1592
  • [7] OXYRADICALS AND CANCER
    CERUTTI, PA
    [J]. LANCET, 1994, 344 (8926) : 862 - 863
  • [8] Design of physicians' health study II - A randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials
    Christen, WG
    Gaziano, JM
    Hennekens, CH
    [J]. ANNALS OF EPIDEMIOLOGY, 2000, 10 (02) : 125 - 134
  • [9] Chylack LT, 2002, OPHTHAL EPIDEMIOL, V9, P49
  • [10] Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5